NeoGenomics (NASDAQ:NEO) Issues FY 2024 Earnings Guidance

NeoGenomics (NASDAQ:NEO) updated its FY 2024 earnings guidance on Tuesday. The company provided earnings per share guidance of 0.080-0.100 for the period, compared to the consensus earnings per share estimate of 0.060. The company issued revenue guidance of $655.0 million-$667.0 million, compared to the consensus revenue estimate of $661.7 million.

Analysts Set New Price Targets

Several brokerages have recently issued reports on NEO. Benchmark reaffirmed a “buy” rating and set a $18.00 price target on shares of NeoGenomics in a research note on Tuesday, September 24th. Needham & Company LLC reiterated a “buy” rating and set a $19.00 price target on shares of NeoGenomics in a research report on Wednesday, September 25th. Finally, Stephens restated an “overweight” rating and issued a $19.00 price objective on shares of NeoGenomics in a report on Tuesday, July 30th. One research analyst has rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $19.89.

NeoGenomics Stock Up 5.7 %

Shares of NEO traded up $0.80 during trading hours on Tuesday, reaching $14.94. The stock had a trading volume of 1,051,223 shares, compared to its average volume of 814,948. NeoGenomics has a 52 week low of $12.77 and a 52 week high of $21.22. The company has a debt-to-equity ratio of 0.37, a current ratio of 2.01 and a quick ratio of 1.93. The firm has a 50-day moving average of $14.75 and a 200 day moving average of $14.71.

About NeoGenomics

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.